DAXSINIG Trademark

Trademark Overview

On Wednesday, June 2, 2021, a trademark application was filed for DAXSINIG with the United States Patent and Trademark Office. The USPTO has given the DAXSINIG trademark a serial number of 90750162. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Wednesday, October 15, 2025. This trademark is owned by Pfizer Inc.. The DAXSINIG trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
daxsinig

General Information

Serial Number90750162
Word MarkDAXSINIG
Filing DateWednesday, June 2, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateWednesday, October 15, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 15, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, August 25, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 100012192
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Tuesday, March 15, 2022PUBLISHED FOR OPPOSITION
Tuesday, March 15, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Saturday, June 5, 2021NEW APPLICATION ENTERED
Wednesday, August 25, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, February 3, 2022ASSIGNED TO EXAMINER
Friday, February 4, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 23, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 10, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Saturday, October 8, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 4, 2023SOU EXTENSION 2 FILED
Tuesday, April 4, 2023SOU EXTENSION 2 GRANTED
Thursday, April 6, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 26, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, April 26, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, October 6, 2022SOU TEAS EXTENSION RECEIVED
Thursday, October 6, 2022SOU EXTENSION 1 FILED
Thursday, October 6, 2022SOU EXTENSION 1 GRANTED
Tuesday, April 4, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, April 26, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, April 26, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, April 26, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Saturday, September 30, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 1, 2024SOU TEAS EXTENSION RECEIVED
Monday, April 1, 2024SOU EXTENSION 4 GRANTED
Thursday, September 28, 2023SOU TEAS EXTENSION RECEIVED
Thursday, September 28, 2023SOU EXTENSION 3 FILED
Thursday, September 28, 2023SOU EXTENSION 3 GRANTED
Tuesday, April 2, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 1, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, October 1, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 1, 2024SOU EXTENSION 5 FILED
Tuesday, October 1, 2024SOU EXTENSION 5 GRANTED
Wednesday, October 15, 2025ABANDONMENT - NO USE STATEMENT FILED
Wednesday, October 15, 2025ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, April 1, 2024SOU EXTENSION 4 FILED

Related Keywords

daxsinig preparations disorders pharmaceutical treatment hypertension pain stroke cancer growth bone